Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99558
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Larance, B. | - |
dc.contributor.author | Mattick, R. | - |
dc.contributor.author | Ali, R. | - |
dc.contributor.author | Lintzeris, N. | - |
dc.contributor.author | Jenkinson, R. | - |
dc.contributor.author | White, N. | - |
dc.contributor.author | Kihas, I. | - |
dc.contributor.author | Cassidy, R. | - |
dc.contributor.author | Degenhardt, L. | - |
dc.contributor.editor | Wilkinson, C. | - |
dc.contributor.editor | Livingston, M. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Drug and Alcohol Review, 2016; 35(1):83-91 | - |
dc.identifier.issn | 0959-5236 | - |
dc.identifier.issn | 1465-3362 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99558 | - |
dc.description.abstract | Introduction and Aims: We report 2 years of post-marketing surveillance of the diversion and injection of buprenorphine-naloxone (BNX) film following its introduction in 2011. Design and Methods: Interviews were conducted with people who inject drugs regularly (PWID) (2004-2013), opioid substitution therapy clients (2013, n = 492) and key experts (n = 44). Key outcomes were unsanctioned removal of supervised doses, diversion, injection and street price. Prevalence of past 6-month injection among PWID was adjusted for background availability of opioid substitution therapy medications using sales data. Results: Among out-of-treatment PWID, the levels of regular (weekly+) BNX film injection were comparable to methadone and BNX tablets, and lower than mono-buprenorphine, adjusting for background availability. Fewer BNX film clients [3%; 95% (CI) 1-5] regularly injected their medication than mono-buprenorphine clients (25%; 95% CI 11-39), but at levels equivalent to those among methadone (3%; 95% CI 1-6) and BNX tablet clients (2%; 95% CI 0-6). Key experts perceived BNX film needed less supervised dosing time as it dissolved rapidly and was harder to remove from the mouth than sublingual tablets; however, removal of supervised doses was higher among BNX film clients (15%; 95% CI: 10-20) than methadone clients (3%; 95% CI 1-6), and not significantly different from BNX tablet (11%; 95% CI 2-21) and mono-buprenorphine clients (31%; 95% CI 16-46). Discussion and Conclusions: Two years post-introduction, levels of BNX film diversion and injection remained comparable with those for methadone and BNX tablets, and lower than mono-buprenorphine. We found no evidence that BNX film has lower non-adherence and diversion than the tablet formulation. | - |
dc.description.statementofresponsibility | Briony Larance, Richard Mattick, Robert Ali, Nicholas Lintzeris, Rebecca Jenkinson, Nancy White, Ivana Kihas, Rosemary Cassidy, Louisa Degenhardt | - |
dc.language.iso | en | - |
dc.publisher | Wiley | - |
dc.rights | © 2015 Australasian Professional Society on Alcohol and other Drug | - |
dc.source.uri | http://dx.doi.org/10.1111/dar.12344 | - |
dc.subject | Opiate substitution treatment; post-marketing product surveillance; patient compliance; opioid-related disorders | - |
dc.title | Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/dar.12344 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1073858 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1041742 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1045318 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ali, R. [0000-0003-2905-8153] | - |
Appears in Collections: | Aurora harvest 3 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.